Is virtual reality exposure therapy (VRET) a safe and recognized treatment for specific phobias?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Virtual Reality Exposure Therapy for Phobias: Safety and Recognition

Virtual reality exposure therapy (VRET) is a safe and recognized treatment for specific phobias, particularly for flying phobia and height phobia, with demonstrated effectiveness comparable to traditional in vivo exposure therapy. 1

Evidence-Based Recognition

VRET has gained formal recognition in clinical guidelines as an effective treatment modality for specific phobias. The 2010 DSM-IV review specifically identifies that virtual reality exposure treatment has been found to be effective for flying phobia and height phobia, while noting that other exposure modalities may be more appropriate for different phobia types 1. This guideline-level recognition establishes VRET as a legitimate therapeutic option within the broader framework of exposure-based treatments.

Safety Profile

No significant safety concerns have been identified with VRET. The most recent high-quality evidence demonstrates:

  • No adverse events or symptom exacerbation occurred in controlled trials 2
  • No increase in average heart rate during VRET sessions 2
  • Attrition rates and deteriorating states are similar to classical CBT approaches 3

The primary safety consideration is virtual reality sickness (similar to motion sickness), which represents a limitation that might prejudice therapy in susceptible individuals 3. However, this is typically manageable and does not constitute a serious safety risk.

Efficacy Evidence

The most recent and highest-quality meta-analysis (2026) demonstrates robust effectiveness:

  • Large effect size for VRET versus waitlist (Hedges' g = -0.98 for phobia symptoms) 4
  • VRET is equivalent to in vivo exposure (g = -0.07, showing no significant difference) 5
  • Treatment gains maintained at 6 months to 1 year 1

Phobia-Specific Effectiveness

Best evidence supports VRET for:

  • Flying phobia - explicitly recognized in guidelines 1
  • Height phobia (acrophobia) - explicitly recognized in guidelines 1 with recent 2025 RCT showing significant reduction in avoidance behavior maintained at 2-month follow-up 6

Emerging evidence for:

  • Dental phobia - 2018 controlled study showed 100% non-overlap data (PND) and four of five participants scheduled dental appointments post-treatment 2
  • Blood-injection-injury phobia - 2020 RCT showed medium to large effects on injection and injury fears (g's = 0.64-1.14), though not sufficient as standalone treatment 7

Less effective for:

  • Claustrophobia - interoceptive exposure and cognitive therapy are more effective 1
  • Animal phobias in children - one-session in vivo exposure is more effective 1

Clinical Advantages

VRET offers specific benefits over traditional exposure:

  • Easy access to feared situations that are difficult or expensive to arrange in real life (e.g., flying, heights)
  • Guaranteed security with complete therapist control
  • Anonymization - patients don't risk encountering acquaintances during exposure
  • Standardization of exposure stimuli
  • Cost reduction over repeated in vivo exposures 3

Important Caveats

VRET does not reach the same level of immersion and presence as in vivo exposure for some specific phobias 8. The "presence feeling" (the sense of "being there") is dependent on both technical features and individual personality factors 3.

VRET should be considered:

  • As an alternative when in vivo exposure is impractical (flying, extreme heights)
  • As an adjunct or interim step before in vivo exposure, particularly for blood-injection-injury phobia 7
  • When patients are highly technophile and may show greater engagement 3

VRET may be less appropriate when:

  • In vivo exposure is readily accessible and practical
  • The patient experiences significant virtual reality sickness
  • The specific phobia type has stronger evidence for other modalities (e.g., applied muscle tension for blood-injection-injury phobia)

Clinical Implementation

The 2020 AACAP guidelines emphasize that graduated exposure is the cornerstone of treatment for anxiety generated by specific situations 9. VRET fits within this framework as a delivery method for graduated exposure, calibrated in intensity similar to medication dosage.

Typical protocol involves:

  • 3-5 sessions over 3-5 weeks 6
  • Therapist-guided exposure with real-time support
  • Standardized fear hierarchy progression
  • Integration with broader CBT framework when appropriate

The evidence supports VRET as both safe and recognized, though clinicians should match the exposure modality to the specific phobia type and individual patient circumstances for optimal outcomes.

References

9
Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Related Questions

Is virtual‑reality exposure therapy FDA approved for the treatment of agoraphobia?
Is virtual reality exposure therapy a recognized, FDA-approved treatment for specific phobias, and is it covered by insurance?
Interpret the arterial blood gas (ABG) values, including pH, partial pressure of carbon dioxide (PaCO₂), partial pressure of oxygen (PaO₂), bicarbonate (HCO₃⁻), and any other relevant measurements such as base excess or lactate.
Are there any studies showing that high-dose creatine improves dementia?
What does a white blood cell count of 6,860/µL with an absolute neutrophil count of 2,401/µL and an absolute lymphocyte count of 3,978/µL indicate in a 68‑year‑old patient?
What are the effects of increased brain creatine levels?
In a 68-year-old man with absolute lymphocytosis suggestive of monoclonal B‑cell lymphocytosis or Rai stage 0 chronic lymphocytic leukemia, how many years is disease progression typically expected before treatment is needed?
In a neutropenic chemotherapy patient presenting with colitis, nausea, vomiting, diarrhea, and fever, should I start empiric therapy with piperacillin‑tazobactam (Zosyn) or cefepime?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.